Provided by Tiger Trade Technology Pte. Ltd.

BioNTech SE

92.52
+1.061.16%
Volume:2.18M
Turnover:202.18M
Market Cap:22.25B
PE:-33.07
High:93.32
Open:91.79
Low:91.54
Close:91.46
52wk High:129.27
52wk Low:81.20
Shares:240.46M
Float Shares:93.81M
Volume Ratio:2.04
T/O Rate:2.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7976
EPS(LYR):-2.8652
ROE:-3.04%
ROA:-2.30%
PB:1.03
PE(LYR):-32.29

Loading ...

Biontech Closes Acquisition Of CureVac

Reuters
·
Dec 18

BioNTech Closes Acquisition of CureVac

Reuters
·
Dec 18

Andon Health Gets US Approval for Flu, COVID-19, RSV Test Kits

MT Newswires Live
·
Dec 15

Berenberg Raises Price Target on BioNTech to $155 From $150, Keeps Buy Rating

MT Newswires Live
·
Dec 11

U.S. RESEARCH ROUNDUP-BioNTtech, GE Vernova, Synopsys

Reuters
·
Dec 11

BioNTech Se : Berenberg Raises Target Price to $155 From $150

THOMSON REUTERS
·
Dec 11

Debate On Vaccine Safety Reaches Policy Stage - FDA Broadens Review Into Covid-19 Shot Risks In Adults

Benzinga
·
Dec 10

Biontech, Bristol Myers Squibb Present Global Phase 2 Data For Pumitamig

Reuters
·
Dec 09

BioNTech and Bristol Myers Squibb Report Positive Phase 2 Results for Pumitamig in Advanced Triple-Negative Breast Cancer

Reuters
·
Dec 09

European Equities Traded in the US as ADRs Little Changed in Monday Trading

MT Newswires Live
·
Dec 09

Sector Update: Health Care Stocks Rise Pre-Bell Monday

MT Newswires Live
·
Dec 08

BioNTech, OncoC4 Say Lung Cancer Phase 3 Trial Shows 'Meaningful' Overall Survival Benefit; Shares Up Pre-Bell

MT Newswires Live
·
Dec 08

Stock Track | BioNTech SE Soars 6.22% on Positive Clinical Trial Results for Lung Cancer Drug

Stock Track
·
Dec 08

Biontech And Oncoc4 Announce Clinically Meaningful Overall Survival Benefit For Lung Cancer Drug

Reuters
·
Dec 08

BioNTech Reports Gotistobart Shows Significant Survival Benefit in Phase 3 Lung Cancer Trial

Reuters
·
Dec 07

BioNTech Secures 81.7% of CureVac Shares in Tender Offer

Reuters
·
Dec 03

BioNTech SE ADR Sheds 5.6%, Underperforms Market

Dow Jones
·
Dec 02

Stock Track | BioNTech SE Plummets 5.02% Intraday Amid FDA Stricter Vaccine Approval Rules

Stock Track
·
Dec 02

Stock Track | BioNTech SE Plummets 5.02% Intraday as FDA Tightens Vaccine Approval Rules

Stock Track
·
Dec 02

Stock Track | BioNTech SE Plummets 5.02% as FDA Proposes Stricter Vaccine Approval Rules

Stock Track
·
Dec 02